PTGS2 and urinary bladder carcinoma: AZD5438, a cyclin-dependent kinase-1/2/9 inhibitor [49], increased COX-2 expression by 1.6–3.5-fold in two out of six tested COX-2-expressing bladder cancer cell lines.